Back

Anti-thrombin nanoparticles for reduce vascular damage and promote functional recovery in acute ischemic kidney injury well after reperfusion

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Preclinical pharmacotherapy Anticoagulants ESC Premium Access ESC Congress 2019

About the speaker

Photo
Associate Professor Hua Pan

WASHINGTON UNIVERSITY MEDICAL CENTER, Saint Louis (United States of America)

8 More presentations in this session

Presentation thumbnail
The KCa2 channel inhibitor AP14145, but not dofetilide or ondansetron, provides functional atrial selectivity in guinea pig hearts
Associate Professor N. Edvardsson (Gothenburg, SE)
Abstract Slides
Presentation thumbnail
Mechanisms of action of the small conductance Ca2+-activated K+-channel modulator AP30663, a novel compound being developed for treatment of atrial fibrillation in man
Mrs S. Bomholtz (Copenhagen N, DK)
Abstract Slides
Presentation thumbnail
The SK channel inhibitor AP30663, converts vernakalant-resistant persistent AF and prevents its reinduction in pigs
Doctor J. Diness (Frederiksberg, DK)
Abstract
Presentation thumbnail
The role of a phosphoinositide-3 kinase inhibitor in vascular inflammation
Miss H. Chaudhry (London, GB)
Abstract Slides
Presentation thumbnail
The small conductance Ca2+-activated K+-channel inhibition tool compound AP14145 protected the guinea pig heart from ventricular arrhythmia during hypokalemia whereas dofetilide was pro-arrhythmic
Professor M. Grunnet (Copenhagen N, DK)
Abstract

Access the full session

Session thumbnail
Poster Session 1 - Preclinical pharmacotherapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources